IRIS UniCatt

De Luca, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.881
EU - Europa 7.661
AS - Asia 7.389
SA - Sud America 1.599
AF - Africa 239
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 10
AN - Antartide 1
Totale 27.791
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.587
SG - Singapore 3.393
DE - Germania 1.950
CN - Cina 1.909
BR - Brasile 1.319
SE - Svezia 1.095
FR - Francia 974
UA - Ucraina 913
PL - Polonia 698
IT - Italia 596
VN - Vietnam 595
IE - Irlanda 388
GB - Regno Unito 324
ID - Indonesia 274
IN - India 269
FI - Finlandia 241
RU - Federazione Russa 185
JP - Giappone 153
HK - Hong Kong 146
BD - Bangladesh 128
CA - Canada 127
TR - Turchia 124
AR - Argentina 114
MX - Messico 80
IQ - Iraq 77
ZA - Sudafrica 69
NL - Olanda 53
PK - Pakistan 44
AT - Austria 43
BE - Belgio 37
ES - Italia 37
EC - Ecuador 35
MA - Marocco 33
CO - Colombia 32
PH - Filippine 32
VE - Venezuela 31
IR - Iran 25
KE - Kenya 25
SA - Arabia Saudita 25
CL - Cile 24
TN - Tunisia 22
JO - Giordania 21
UZ - Uzbekistan 20
EG - Egitto 17
PY - Paraguay 17
JM - Giamaica 16
KR - Corea 15
LT - Lituania 15
AE - Emirati Arabi Uniti 14
PE - Perù 14
AZ - Azerbaigian 13
CH - Svizzera 13
DZ - Algeria 13
HN - Honduras 12
BZ - Belize 11
KZ - Kazakistan 11
NP - Nepal 11
RO - Romania 11
ET - Etiopia 10
IL - Israele 10
MD - Moldavia 10
BG - Bulgaria 9
GT - Guatemala 9
OM - Oman 9
BO - Bolivia 8
CI - Costa d'Avorio 8
CM - Camerun 8
GR - Grecia 8
TT - Trinidad e Tobago 8
CZ - Repubblica Ceca 7
DO - Repubblica Dominicana 7
EU - Europa 7
HU - Ungheria 7
KG - Kirghizistan 7
QA - Qatar 7
AU - Australia 6
LB - Libano 6
MY - Malesia 6
PA - Panama 6
PS - Palestinian Territory 6
AL - Albania 5
AO - Angola 5
BY - Bielorussia 5
DK - Danimarca 5
LK - Sri Lanka 5
LU - Lussemburgo 5
NI - Nicaragua 5
NZ - Nuova Zelanda 5
PT - Portogallo 5
AM - Armenia 4
EE - Estonia 4
GE - Georgia 4
NG - Nigeria 4
PR - Porto Rico 4
SN - Senegal 4
TW - Taiwan 4
UY - Uruguay 4
BH - Bahrain 3
LA - Repubblica Popolare Democratica del Laos 3
RS - Serbia 3
Totale 27.725
Salva come PNG Salva come JPEG
Città #
Singapore 1.627
Chandler 1.369
Ashburn 1.355
San Jose 971
Jacksonville 575
Kraków 520
San Mateo 406
Dublin 383
New York 379
Beijing 362
Dearborn 287
Nanjing 275
Jakarta 242
Wilmington 231
Lauterbourg 225
Ho Chi Minh City 207
Houston 179
Ann Arbor 171
Warsaw 164
Lawrence 161
Los Angeles 161
Boston 155
Cattolica 151
Redmond 143
Hangzhou 139
Hefei 136
Hanoi 134
Woodbridge 132
Hong Kong 131
Tokyo 131
Milan 110
Seattle 110
Dallas 109
Moscow 107
Nürnberg 106
Nanchang 102
São Paulo 94
Frankfurt am Main 93
Redwood City 91
Izmir 80
Lancaster 76
Princeton 75
Boardman 74
Mountain View 67
Santa Clara 65
University Park 64
Buffalo 59
Munich 58
Shenyang 58
The Dalles 58
Chicago 56
Paris 56
Fairfield 54
Guangzhou 50
Kunming 48
Orem 46
Rio de Janeiro 45
Rome 44
Bremen 43
Hebei 43
Norwalk 43
Atlanta 42
Changsha 41
Johannesburg 40
Brussels 36
Kent 36
Shanghai 35
Fremont 34
Jiaxing 34
London 34
Marseille 34
Da Nang 32
Memphis 31
Ottawa 31
Philadelphia 31
Belo Horizonte 30
Nuremberg 30
Pune 30
Tianjin 30
Montreal 29
Falls Church 28
Jinan 28
Amsterdam 27
Haiphong 27
Brasília 26
Brooklyn 25
Cambridge 25
Helsinki 25
Verona 25
Zhengzhou 25
Toronto 24
Düsseldorf 22
Las Vegas 22
San Francisco 22
Leawood 21
Mexico City 21
Scottsdale 21
Vienna 21
Washington 21
Amman 20
Totale 14.802
Salva come PNG Salva come JPEG
Nome #
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 386
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 327
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 269
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 265
Common genetic variation and the control of HIV-1 in humans. 257
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 255
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 230
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 217
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 210
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 199
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 197
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 191
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 188
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 188
Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120 186
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 184
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 183
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 179
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 178
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 177
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 176
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 171
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 171
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 170
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 169
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 169
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 168
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 168
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 167
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 167
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 166
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 164
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 159
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 158
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 158
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 157
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 157
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 157
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 156
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 154
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 153
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 153
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 153
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 153
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 151
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 151
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 149
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 148
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop 148
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 148
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 147
Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania 147
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 147
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 147
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group 145
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 144
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 144
Long term follow-up of Nevirapine-treated patients in a single centre cohort 141
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 140
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 140
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 140
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 140
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 140
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 139
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 139
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 139
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). 138
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 138
Phemphigus vulgaris in a human-immunodeficiency-virus-infected patient. 137
Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients 136
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen 136
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 136
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 135
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 135
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 135
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors 134
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 134
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 133
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 130
A novel methodology for large-scale phylogeny partition 129
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 129
Evolution and predictors of HIV type 1 drug resistance in patients failing combination antiretroviral therapy in Italy 129
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 129
Lipid-lowering effect of tenofovir in HIV-infected patients 127
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study 127
Determinants of survival in progressive multifocal leucoencephalopathy 126
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases 125
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 125
Hyperbilirubinemia during atazanavir treatment in 2404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 125
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 124
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 123
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 123
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 123
Stochastic Modelling of Genotypic Drug-Resistance for Human Immunodeficiency Virus towards Long-Term Combination Therapy Optimisation 122
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 122
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 121
[Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)] 121
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 121
An outbreak of HIV-1 subtype G among Italian injecting drug users 120
Interpretation systems for genotypic drug resistance of HIV-1 120
Totale 15.902
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.967
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.967
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202139 0 0 0 0 0 0 0 0 0 0 0 39
2021/20221.870 185 198 43 94 68 81 31 315 70 137 260 388
2022/20233.527 475 477 286 502 307 453 82 297 448 36 106 58
2023/20241.724 73 554 31 136 51 379 79 34 18 28 190 151
2024/20253.232 83 101 269 76 277 131 101 207 568 269 578 572
2025/20269.294 1.462 271 576 1.026 1.526 469 1.598 464 615 793 263 231
Totale 28.066